Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flexible joint model for time-to-event and non-Gaussian longitudinal outcomes.

Statistical methods in medical research·2024
Same author

Second Birth Fertility in Germany: Social Class, Gender, and the Role of Economic Uncertainty.

European journal of population = Revue europeenne de demographie·2023
Same author

Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug Disposition.

Drug metabolism and disposition: the biological fate of chemicals·2022
Same author

Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401).

Clinical pharmacology and therapeutics·2022
Same author

Formative Assessment of Diagnostic Testing in Family Medicine with Comprehensive MCQ Followed by Certainty-Based Mark.

Healthcare (Basel, Switzerland)·2022
Same author

Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment.

CPT: pharmacometrics & systems pharmacology·2022

Related Experiment Video

Updated: Jul 5, 2026

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.

Astrid Jullion1, Philippe Lambert, Benoit Beck

  • 1Institut de Statistique, Université Catholique de Louvain, Louvain-la-Neuve, Belgium. astrid.jullion@ucb-group.com

Pharmaceutical Statistics
|May 16, 2008
PubMed
Summary
This summary is machine-generated.

A new Bayesian nonparametric model using P-splines accurately estimates pharmacokinetic (PK) parameters from drug concentration data. This method improves upon interpolation and compartmental modeling, especially with sparse or noisy data, providing reliable AUC and half-life estimations.

More Related Videos

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

Related Experiment Videos

Last Updated: Jul 5, 2026

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

Area of Science:

  • Pharmacokinetics
  • Statistical Modeling
  • Computational Biology

Background:

  • Pharmacokinetic (PK) studies analyze drug concentration over time to determine key parameters like AUC, C(max), t(max), and t(1/2).
  • Traditional methods such as linear interpolation and compartmental modeling have limitations, particularly with sparse or noisy preclinical and clinical data, leading to convergence issues and model selection challenges.

Purpose of the Study:

  • To introduce a novel Bayesian nonparametric model based on P-splines for robust estimation of PK parameters.
  • To evaluate the performance of this new method against existing interpolation and compartmental modeling techniques.

Main Methods:

  • Development of a Bayesian nonparametric model utilizing P-splines to estimate PK parameters.
  • Application of the model to analyze drug concentration-time data, including hierarchical extensions for multi-subject analysis.
  • Comparison of estimation accuracy (bias and precision) with linear interpolation and compartmental modeling through simulations.

Main Results:

  • The proposed Bayesian nonparametric P-spline method demonstrates superior PK parameter estimation compared to linear interpolation, exhibiting reduced bias and improved precision.
  • While a correctly specified compartmental model excels in estimating t(max) and C(max), the Bayesian nonparametric approach provides better estimations for AUC and t(1/2).
  • The hierarchical extension allows for individual PK parameter estimation and provides uncertainty measures through credibility sets.

Conclusions:

  • The Bayesian nonparametric P-spline model offers a flexible and accurate approach for PK parameter estimation, outperforming traditional methods, especially in scenarios with limited or noisy data.
  • This method enhances the reliability of PK analysis and provides valuable insights into drug behavior in preclinical and clinical settings.
  • The ability to generate individual parameter estimates and uncertainty quantification makes this a powerful tool for drug development.